A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix

A Southwest Oncology Group trial

Geoffrey R. Weiss, P. Y. Liu, Janet O'Sullivan, David S Alberts, Thomas D. Brown, John R. Neefe, Laura F. Hutchins

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Patients with measurable metastatic or recurrent squamous carcinoma of the uterine cervix who had failed prior surgery or radiation therapy were enrolled on this randomized phase II study. Twenty-seven eligible patients were assigned to receive didemnin B at either 2.6 mg/m2 iv every 28 days (sixteen patients) or at 5.6 mg/m2 (eleven patients). Sixteen patients were assigned to receive 12 mg/m2/day iv trimetrexate for 5 days, repeated every 21 days. Toxicity for didemnin B was characterized by nausea and vomiting (78% of patients), anemia (59%), mild diarrhea (11%), and episodic hypersensitivity (three patients). Toxicity for trimetrexate included nausea and vomiting (69%), leukopenia (51%), mild thrombocytopenia (38%), anemia (63%), and diarrhea (31%). No antitumor responses were observed for either agent. Neither trimetrexate nor didemnin B at these doses and schedules is recommended for the treatment of advanced squamous carcinoma of the uterine cervix.

Original languageEnglish (US)
Pages (from-to)303-306
Number of pages4
JournalGynecologic Oncology
Volume45
Issue number3
DOIs
StatePublished - 1992

Fingerprint

didemnins
Trimetrexate
Cervix Uteri
Squamous Cell Carcinoma
Nausea
Therapeutics
Vomiting
Anemia
Diarrhea
Leukopenia
Thrombocytopenia
Appointments and Schedules
Hypersensitivity
Radiotherapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix : A Southwest Oncology Group trial. / Weiss, Geoffrey R.; Liu, P. Y.; O'Sullivan, Janet; Alberts, David S; Brown, Thomas D.; Neefe, John R.; Hutchins, Laura F.

In: Gynecologic Oncology, Vol. 45, No. 3, 1992, p. 303-306.

Research output: Contribution to journalArticle

Weiss, Geoffrey R. ; Liu, P. Y. ; O'Sullivan, Janet ; Alberts, David S ; Brown, Thomas D. ; Neefe, John R. ; Hutchins, Laura F. / A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix : A Southwest Oncology Group trial. In: Gynecologic Oncology. 1992 ; Vol. 45, No. 3. pp. 303-306.
@article{5d356dc2b928470381d8be1e75823662,
title = "A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: A Southwest Oncology Group trial",
abstract = "Patients with measurable metastatic or recurrent squamous carcinoma of the uterine cervix who had failed prior surgery or radiation therapy were enrolled on this randomized phase II study. Twenty-seven eligible patients were assigned to receive didemnin B at either 2.6 mg/m2 iv every 28 days (sixteen patients) or at 5.6 mg/m2 (eleven patients). Sixteen patients were assigned to receive 12 mg/m2/day iv trimetrexate for 5 days, repeated every 21 days. Toxicity for didemnin B was characterized by nausea and vomiting (78{\%} of patients), anemia (59{\%}), mild diarrhea (11{\%}), and episodic hypersensitivity (three patients). Toxicity for trimetrexate included nausea and vomiting (69{\%}), leukopenia (51{\%}), mild thrombocytopenia (38{\%}), anemia (63{\%}), and diarrhea (31{\%}). No antitumor responses were observed for either agent. Neither trimetrexate nor didemnin B at these doses and schedules is recommended for the treatment of advanced squamous carcinoma of the uterine cervix.",
author = "Weiss, {Geoffrey R.} and Liu, {P. Y.} and Janet O'Sullivan and Alberts, {David S} and Brown, {Thomas D.} and Neefe, {John R.} and Hutchins, {Laura F.}",
year = "1992",
doi = "10.1016/0090-8258(92)90309-7",
language = "English (US)",
volume = "45",
pages = "303--306",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix

T2 - A Southwest Oncology Group trial

AU - Weiss, Geoffrey R.

AU - Liu, P. Y.

AU - O'Sullivan, Janet

AU - Alberts, David S

AU - Brown, Thomas D.

AU - Neefe, John R.

AU - Hutchins, Laura F.

PY - 1992

Y1 - 1992

N2 - Patients with measurable metastatic or recurrent squamous carcinoma of the uterine cervix who had failed prior surgery or radiation therapy were enrolled on this randomized phase II study. Twenty-seven eligible patients were assigned to receive didemnin B at either 2.6 mg/m2 iv every 28 days (sixteen patients) or at 5.6 mg/m2 (eleven patients). Sixteen patients were assigned to receive 12 mg/m2/day iv trimetrexate for 5 days, repeated every 21 days. Toxicity for didemnin B was characterized by nausea and vomiting (78% of patients), anemia (59%), mild diarrhea (11%), and episodic hypersensitivity (three patients). Toxicity for trimetrexate included nausea and vomiting (69%), leukopenia (51%), mild thrombocytopenia (38%), anemia (63%), and diarrhea (31%). No antitumor responses were observed for either agent. Neither trimetrexate nor didemnin B at these doses and schedules is recommended for the treatment of advanced squamous carcinoma of the uterine cervix.

AB - Patients with measurable metastatic or recurrent squamous carcinoma of the uterine cervix who had failed prior surgery or radiation therapy were enrolled on this randomized phase II study. Twenty-seven eligible patients were assigned to receive didemnin B at either 2.6 mg/m2 iv every 28 days (sixteen patients) or at 5.6 mg/m2 (eleven patients). Sixteen patients were assigned to receive 12 mg/m2/day iv trimetrexate for 5 days, repeated every 21 days. Toxicity for didemnin B was characterized by nausea and vomiting (78% of patients), anemia (59%), mild diarrhea (11%), and episodic hypersensitivity (three patients). Toxicity for trimetrexate included nausea and vomiting (69%), leukopenia (51%), mild thrombocytopenia (38%), anemia (63%), and diarrhea (31%). No antitumor responses were observed for either agent. Neither trimetrexate nor didemnin B at these doses and schedules is recommended for the treatment of advanced squamous carcinoma of the uterine cervix.

UR - http://www.scopus.com/inward/record.url?scp=0026720219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026720219&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(92)90309-7

DO - 10.1016/0090-8258(92)90309-7

M3 - Article

VL - 45

SP - 303

EP - 306

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -